Modality
ASO
MOA
CD47i
Target
KRASG12D
Pathway
Cell Cycle
CRCIgANDravet
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
Aug 2021
→ Oct 2028
Phase 3Current
NCT06783299
1,924 pts·IgAN
2021-08→2028-10·Recruiting
1,924 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-052.5y awayPh3 Readout· IgAN
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Recruit…
Catalysts
Ph3 Readout
2028-10-05 · 2.5y away
IgAN
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06783299 | Phase 3 | IgAN | Recruiting | 1924 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Zenonesiran | GSK | Preclinical | DLL3 |